RU2016103771A - Синтетические вакцины против streptococcus pneumoniae 1-го типа - Google Patents

Синтетические вакцины против streptococcus pneumoniae 1-го типа Download PDF

Info

Publication number
RU2016103771A
RU2016103771A RU2016103771A RU2016103771A RU2016103771A RU 2016103771 A RU2016103771 A RU 2016103771A RU 2016103771 A RU2016103771 A RU 2016103771A RU 2016103771 A RU2016103771 A RU 2016103771A RU 2016103771 A RU2016103771 A RU 2016103771A
Authority
RU
Russia
Prior art keywords
compound
general formula
galap
defined above
trideoxy
Prior art date
Application number
RU2016103771A
Other languages
English (en)
Russian (ru)
Inventor
Петер Х. ЗЕЕБЕРГЕР
Клейни Лебев ПЕРЕЙРА
Чаккумкал АНИШ
Бенджамин ШУМАНН
Original Assignee
Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13183826.0A external-priority patent/EP2845860A1/en
Application filed by Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. filed Critical Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф.
Publication of RU2016103771A publication Critical patent/RU2016103771A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G01N2333/3156—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae [Pneumococcus]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
RU2016103771A 2013-07-07 2014-07-07 Синтетические вакцины против streptococcus pneumoniae 1-го типа RU2016103771A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13175447.5 2013-07-07
EP13175447 2013-07-07
EP13183826.0 2013-09-10
EP13183826.0A EP2845860A1 (en) 2013-09-10 2013-09-10 Synthetic vaccines against Streptococcus pneumoniae
EP13196568 2013-12-10
EP13196568.3 2013-12-10
PCT/EP2014/064407 WO2015004041A1 (en) 2013-07-07 2014-07-07 Synthetic vaccines against streptococcus pneumoniae type 1

Publications (1)

Publication Number Publication Date
RU2016103771A true RU2016103771A (ru) 2017-08-11

Family

ID=51257468

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016103771A RU2016103771A (ru) 2013-07-07 2014-07-07 Синтетические вакцины против streptococcus pneumoniae 1-го типа

Country Status (15)

Country Link
US (1) US10328141B2 (enExample)
EP (1) EP3019513B1 (enExample)
JP (1) JP6416249B2 (enExample)
KR (1) KR102250099B1 (enExample)
CN (1) CN105492454B (enExample)
AU (1) AU2014289342B2 (enExample)
BR (1) BR112016000210A2 (enExample)
CA (1) CA2917365A1 (enExample)
HK (1) HK1224300A1 (enExample)
IL (1) IL243452B (enExample)
MX (1) MX2016000099A (enExample)
RU (1) RU2016103771A (enExample)
SG (1) SG11201600042YA (enExample)
WO (1) WO2015004041A1 (enExample)
ZA (1) ZA201600136B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP6622804B2 (ja) * 2014-12-12 2019-12-18 マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー ストレプトコッカス ニューモニアエ(Streptococcus pneumoniae)血清型4に対するワクチン
CN109311924B (zh) * 2016-04-14 2020-04-17 马克斯·普朗克科学促进学会 针对肺炎链球菌3型的疫苗的改善的制备
CN111183472A (zh) 2017-07-17 2020-05-19 3M创新有限公司 弯曲限制膜
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム O-結合型グリコシル化のための修飾キャリアタンパク質
IL305675A (en) * 2021-03-19 2023-11-01 Mitochondria Emotion Inc Cyclopropane analogues of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide and related compounds
JP7714690B2 (ja) 2021-05-28 2025-07-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
WO2005046722A2 (en) 2003-11-05 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
PL1885734T3 (pl) * 2005-05-06 2015-08-31 Novartis Ag Immunogeny dla szczepionek przeciwko Meningitidis-A
CA2797052A1 (en) * 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphyloccocus vaccine
WO2011137181A1 (en) * 2010-04-27 2011-11-03 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for moraxella vaccine

Also Published As

Publication number Publication date
KR102250099B1 (ko) 2021-05-10
JP6416249B2 (ja) 2018-10-31
US20160346374A1 (en) 2016-12-01
JP2016526564A (ja) 2016-09-05
ZA201600136B (en) 2017-04-26
SG11201600042YA (en) 2016-02-26
BR112016000210A2 (pt) 2017-08-22
US10328141B2 (en) 2019-06-25
MX2016000099A (es) 2016-07-07
WO2015004041A1 (en) 2015-01-15
EP3019513B1 (en) 2018-01-17
AU2014289342B2 (en) 2018-05-31
AU2014289342A1 (en) 2016-01-28
HK1224300A1 (zh) 2017-08-18
IL243452B (en) 2019-02-28
CN105492454B (zh) 2019-09-27
KR20160029844A (ko) 2016-03-15
EP3019513A1 (en) 2016-05-18
CN105492454A (zh) 2016-04-13
CA2917365A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
JP2016526564A5 (enExample)
EP3019513B1 (en) Synthetic vaccines against streptococcus pneumoniae type 1
AU2015323651B2 (en) Vaccines against Streptococcus pneumoniae serotype 8
JP2010132925A5 (enExample)
US10596272B2 (en) Vaccines against Streptococcus pneumoniae serotype 5
JP2020514414A (ja) 糖結合タンパク質を隔離する糖ポリマー
JP2019508468A (ja) 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法
IL259289A (en) Synthetic vaccines against streptoccocus pneumoniae serotype 2
EP2500349B1 (en) Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
BE1024634B1 (fr) Compositions immunogenes
WO2014170681A9 (en) Oligosaccharide conjugates and methods of use
NZ517464A (en) Oligosaccharides derived from ribose-ribitol-phosphate, and vaccines containing them
ES2556951T3 (es) Polisacárido ramno del complejo clonal 17 de Enterococcus faecium y usos del mismo
Karki et al. Synthetic directions towards capsular polysaccharide of Streptococcus pneumoniae serotype 18C
Arar et al. A polysaccharide of Alloiococcus otitidis, a new pathogen of otitis media: chemical structure and synthesis of a neoglycoconjugate thereof
Jalsa et al. A unique approach to the synthesis of a dengue vaccine and the novel tetrasaccharide that results
Kovác Studies toward a rationally designed conjugate vaccine for cholera using synthetic carbohydrate antigens
JP2024180376A (ja) 化合物、免疫増強剤、ワクチン組成物及び粘膜ワクチン組成物
EP2845860A1 (en) Synthetic vaccines against Streptococcus pneumoniae
Seeberger et al. Synthetic vaccines against Streptococcus pneumoniae
EP3000820A1 (en) Synthetic vaccines against Streptococcus pneumoniae serotype 8
RU2020112316A (ru) Способы получения составов пневмококковых полисахаридов для конъюгации с белком-носителем
HK1242329A1 (en) Vaccines against streptococcus pneumoniae serotype 8
HK1242329B (en) Vaccines against streptococcus pneumoniae serotype 8

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20170710